Weight Watchers (WW) Q2 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q2 2026 earnings summary
5 Aug, 2026Executive summary
Emerged from Chapter 11 bankruptcy in June 2025, applying fresh start accounting and establishing a new capital structure, resulting in non-comparable Predecessor and Successor periods.
Achieved ongoing progress in multi-year transformation, with improved financial footing, positive operating cash flow in Q2, and reaffirmed full-year 2026 revenue and adjusted EBITDA guidance.
Q2 2026 revenue was $162.3 million, down 14% year-over-year, driven by Behavioral declines but offset by strong Clinical growth.
Net income for Q2 2026 was $14.1 million, including a $4.6 million gain from debt extinguishment; diluted EPS was $1.41.
Leadership transition occurred in March 2026, with the CEO resigning and an Interim Office of the Chief Executive established.
Financial highlights
Q2 2026 revenue: $162.3 million (down 14% year-over-year); ARPU increased 10.2% to $20.90 due to a shift to higher-value tiers.
Clinical subscription revenue grew 30.4% to $39.9 million, now 24.6% of total revenue; Behavioral subscription revenue declined 22.7% to $121.5 million.
Q2 net income was $14.1 million; adjusted EBITDA was $39.8 million (24.5% margin); Q2 gross margin was 70.3%, with adjusted gross margin at 73.6%.
Marketing expense was $47.9 million (29.5% of revenue), higher than prior year due to reorganization.
Cash and cash equivalents at June 30, 2026, were $101.5 million.
Outlook and guidance
Full-year 2026 revenue guidance reaffirmed at $620–$635 million and adjusted EBITDA at $105–$115 million.
Clinical subscription revenue expected to represent 25–30% of 2026 total revenue.
Continued growth in Core+ subscribers and moderation in behavioral subscriber declines anticipated.
Expect positive operating cash flow for full year 2026; no need for additional liquidity anticipated in the next 12 months.
Management expects continued market disruption and competitive pressures, especially from rapid adoption of GLP-1 medications and new entrants.
Latest events from Weight Watchers
- Board urges support for director nominees and revamped executive compensation post-bankruptcy.WW
Proxy filing - Settlement with former CEO includes major payments and mutual covenants amid leadership transition.WW
Proxy filing - Clinical growth and strong margins offset net loss; 2026 guidance and debt reduction reaffirmed.WW
Q1 2026 - Shareholders will vote on directors, auditor, and executive pay after a transformative restructuring.WW
Proxy filing - Clinical subscriber growth and higher ARPU drive 2026 outlook despite behavioral headwinds.WW
Q4 2025 - GLP-1 integration, financial restructuring, and targeted programs drive innovation and growth.WW
CJS Securities 26th Annual "New Ideas for the New Year” Investor Conference - Q3 revenue and subscribers fell, but clinical growth and cost actions supported margin gains.WW
Q3 2024 - Q2 2024 revenue fell 10.9% as clinical subscribers surged 120% and cost savings were targeted.WW
Q2 2024 - Clinical growth and cost cuts offset declines, but bankruptcy and high debt loom.WW
Q1 2025